Drugs facing NCE-1 in 2030

Drugs becoming eligible for first Paragraph IV ANDA filing in 2030

1. Adquey patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE46792 ACROTECH NA
Mar, 2028

(1 year, 3 months from now)

US10588893 ACROTECH Ointment Containing An Oxazole Compound
Dec, 2036

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 12, 2031

Drugs and Companies using DIFAMILAST ingredient

NCE-1 date: 12 February, 2030

Market Authorisation Date: 12 February, 2026

Treatment: Method of treating atopic dermatitis

Dosage: OINTMENT

More Information on Dosage

ADQUEY family patents

Family Patents

2. Ambelvist patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10137209 BAYER Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging
May, 2036

(9 years from now)

US12478696 BAYER Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging
May, 2036

(9 years from now)

US11491245 BAYER Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging
May, 2036

(9 years from now)

US10722601 BAYER Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging
May, 2036

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12303573 BAYER Formulation Of Contrast Media And Process Of Preparation Thereof
Nov, 2039

(13 years from now)

US11944690 BAYER Formulation Of Contrast Media And Process Of Preparation Thereof
May, 2040

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 12, 2031

Drugs and Companies using GADOQUATRANE ingredient

NCE-1 date: 12 June, 2030

Market Authorisation Date: 12 June, 2026

Treatment: Method of magnetic resonance imaging to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax,...

Dosage: SOLUTION

More Information on Dosage

AMBELVIST family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Atebrioz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10710980 MIRUM Aminopyridine Derivatives And Their Use As Selective Alk-2 Inhibitors
Jul, 2037

(10 years from now)

US12466808 MIRUM Aminopyridine Derivatives And Their Use As Selective Alk-2 Inhibitors
May, 2039

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10947218 MIRUM Aminopyridine Derivatives And Their Use As Selective Alk-2 Inhibitors
Jul, 2037

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 25, 2031

Drugs and Companies using ZILURGISERTIB FUMARATE ingredient

NCE-1 date: 25 September, 2030

Market Authorisation Date: 25 September, 2026

Treatment: Reduce the volume of total new heterotopic ossification (ho) in adults and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (fop)

Dosage: TABLET

More Information on Dosage

ATEBRIOZ family patents

Family Patents

4. Baxfendy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9353081 ASTRAZENECA Bicyclic Dihydroquinoline-2-One Derivatives
Feb, 2033

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 15, 2031

Drugs and Companies using BAXDROSTAT ingredient

NCE-1 date: 15 May, 2030

Market Authorisation Date: 15 May, 2026

Treatment: NA

Dosage: TABLET

More Information on Dosage

BAXFENDY family patents

Family Patents

5. Beqalzi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11420968 BEONE MEDICINES Bcl-2 Inhibitors
Apr, 2039

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 13, 2031

Drugs and Companies using SONROTOCLAX ingredient

NCE-1 date: 13 May, 2030

Market Authorisation Date: 13 May, 2026

Treatment: NA

Dosage: TABLET

More Information on Dosage

BEQALZI family patents

Family Patents

6. Bysanti patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10570453 VANDA Method Of Predicting A Predisposition To Qt Prolongation
Mar, 2028

(1 year, 4 months from now)

US9157121 VANDA Method of treatment based on polymorphisms of the KCNQ1 gene
Apr, 2030

(3 years from now)

US10563259 VANDA Method Of Treatment Based On Polymorphisms Of The Kcnq1 Gene
Jul, 2030

(3 years from now)

US12606869 VANDA Methods For The Administration Of Iloperidone
Sep, 2030

(3 years from now)

US8999638 VANDA Method of treatment based on polymorphisms of the KCNQ1 gene
Oct, 2030

(3 years from now)

US9074255 VANDA Method of predicting a predisposition to QT prolongation
Dec, 2030

(4 years from now)

US9072742 VANDA Method of predicting a predisposition to QT prolongation
Jan, 2031

(4 years from now)

US9074256 VANDA Method of predicting a predisposition to QT prolongation
Feb, 2031

(4 years from now)

US9074254 VANDA Method of predicting a predisposition to QT prolongation
Dec, 2031

(5 years from now)

US12478619 VANDA Method Of Treatment With Milsaperidone
May, 2044

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 20, 2031

Drugs and Companies using MILSAPERIDONE ingredient

NCE-1 date: 20 February, 2030

Market Authorisation Date: 20 February, 2026

Treatment: Method for acute treatment of manic or mixed episodes associated with bipolar i disorder in adults by administering milsaperidone to a patient by lowering the dose after determining that the patient h...

Dosage: TABLET

More Information on Dosage

BYSANTI family patents

Family Patents

7. Cypsedo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9517988 HAISCO Phenol Derivative And Preparation Method And Use In Medicine Thereof
May, 2034

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10729666 HAISCO Use Of Gabaa Receptor Reinforcing Agent In Preparation Of Sedative And Anesthetic Medicament
May, 2034

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 27, 2031

Drugs and Companies using CIPEPOFOL ingredient

NCE-1 date: 27 August, 2030

Market Authorisation Date: 27 August, 2026

Treatment: Inducing general anesthesia in adults undergoing surgery

Dosage: EMULSION

More Information on Dosage

CYPSEDO family patents

Family Patents

8. Emcitate patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12611383 RARE THYROID NA
Jul, 2045

(18 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 28, 2031

Drugs and Companies using TIRATRICOL ingredient

NCE-1 date: 28 September, 2030

Market Authorisation Date: 28 September, 2026

Treatment: Treatment of peripheral thyrotoxicosis in adults and pediatric patients with mct8 deficiency (allan-herndon-dudley syndrome) by administering tiratricol

Dosage: TABLET, FOR SUSPENSION

More Information on Dosage

EMCITATE family patents

Family Patents

9. Etcamah patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10131663 ASTRAZENECA Chemical Compounds
Oct, 2037

(10 years from now)

US10590130 ASTRAZENECA Chemical Compounds
Oct, 2037

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10961241 ASTRAZENECA Chemical Compounds
Oct, 2037

(10 years from now)

US12077530 ASTRAZENECA Chemical Compounds
Oct, 2037

(10 years from now)

US12364689 ASTRAZENECA Dosage Regimen For The Treatment Of Cancer
Sep, 2041

(14 years from now)

US12453729 ASTRAZENECA Pharmaceutical Formulations
Oct, 2041

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 04, 2031

Drugs and Companies using CAMIZESTRANT ingredient

NCE-1 date: 04 September, 2030

Market Authorisation Date: 04 September, 2026

Treatment: Treatment with a cdk4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) of hr-pos., her2-neg. locally advanced or metastatic breast cancer upon detection of esr1 mutation during aromatase inhibito...

Dosage: TABLET

More Information on Dosage

ETCAMAH family patents

Family Patents

10. Foundayo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE50455 ELI LILLY NA
Sep, 2037

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 01, 2031

Drugs and Companies using ORFORGLIPRON CALCIUM ingredient

NCE-1 date: 01 April, 2030

Market Authorisation Date: 01 April, 2026

Treatment: Treatment to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with at least one weight-related comorbid condition by administering an effective am...

Dosage: TABLET

More Information on Dosage

FOUNDAYO family patents

Family Patents